Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 Mar;114(6):1110–1116. doi: 10.1111/j.1476-5381.1995.tb13322.x

Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ETA sub-type.

A P Davenport 1, G O'Reilly 1, R E Kuc 1
PMCID: PMC1510347  PMID: 7620699

Abstract

1. We measured the ratio of ETA and ETB sub-types in the media (containing mainly smooth muscle) of human cardiac arteries (aorta, pulmonary and coronary), internal mammary arteries and saphenous veins. 2. In saturation experiments, [125I]-endothelin-1 ([125I]-ET-1) bound with high affinity to the media of each vessel (n = 3 individuals or homogenate preparations +/- s.e. mean): coronary artery, KD = 0.14 +/- 0.02 nM, Bmax = 71.0 +/- 21.0 fmol mg-1 protein; pulmonary artery, KD = 0.85 +/- 0.25 nM, Bmax = 15.2 +/- 10.3 fmol mg-1 protein; aorta, KD = 0.51 +/- 0.02 nM, Bmax = 9.4 +/- 4.4 fmol mg-1 protein; internal mammary artery. KD = 0.34 +/- 0.31 nM, Bmax = 2.0 +/- 0.5 fmol mg-1 protein and saphenous vein, KD = 0.28 +/- 0.05 nM, Bmax = 52.8 +/- 1.0 fmol mg-1 protein. In each vessel, over the concentration-range tested, Hill slopes were close to unity and a one site fit was preferred to a two site model. 3. In competition binding assays, the ETA selective ligand, BQ123 inhibited the binding of 0.1 nM [125I]-ET-1 to the media in a biphasic manner. In each case, a two site fit was preferred to a one or three site model: coronary artery, KDETA = 0.85 +/- 0.03 nM, KDETB = 7.58 +/- 2.27 microM, ratio = 89:11%; pulmonary artery, KDETA = 0.27 +/- 0.05 nM, KDETB = 24.60 +/- 5.34 microM, ratio = 92:8%; aorta, KDETA = 0.80 +/- 0.40 nM, KDETB = 2.67 +/- 2.60 microM ratio = 89:11%; saphenous vein, KDETA = 0.55 +/- 0.17 nM, KDETB = 14.4 +/- 0.26 microM, 85:15% (n = 3 individuals or homogenate preparations +/- s.e. mean). BQ123 showed up to 18000 fold selectivity for the ETA over the ETB sub-type. The ETA-selective ligand, [125I]-PD151242 labelled 85% of the receptors detected by a fixed concentration of [125I]-ET-1 in media of internal mammary artery, measured by quantitative autoradiography. In contrast, the density of ETB receptors detected with [125I]-BQ3020 was 7.0 +/- 1.5 amol mm-2, representing about 8% of [125I]-ET-1.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
1110

Images in this article

1114Figure 2
on p.1114

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akar F., Uydes B. S., Ayrancioğlu K., Yener A., Aşlamaci S., Arsan M., Törüner A., Kanzik I. Endothelial function of human gastroepiploic artery in comparison with saphenous vein. Cardiovasc Res. 1994 Apr;28(4):500–504. doi: 10.1093/cvr/28.4.500. [DOI] [PubMed] [Google Scholar]
  2. Bax W. A., Bruinvels A. T., van Suylen R. J., Saxena P. R., Hoyer D. Endothelin receptors in the human coronary artery, ventricle and atrium. A quantitative autoradiographic analysis. Naunyn Schmiedebergs Arch Pharmacol. 1993 Oct;348(4):403–410. doi: 10.1007/BF00171340. [DOI] [PubMed] [Google Scholar]
  3. Bigaud M., Pelton J. T. Discrimination between ETA- and ETB-receptor-mediated effects of endothelin-1 and [Ala1,3,11,15]endothelin-1 by BQ-123 in the anaesthetized rat. Br J Pharmacol. 1992 Dec;107(4):912–918. doi: 10.1111/j.1476-5381.1992.tb13385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bodelsson G., Stjernquist M. Characterization of endothelin receptors and localization of 125I-endothelin-1 binding sites in human umbilical artery. Eur J Pharmacol. 1993 Nov 16;249(3):299–305. doi: 10.1016/0014-2999(93)90526-n. [DOI] [PubMed] [Google Scholar]
  5. Clozel M., Gray G. A., Breu V., Löffler B. M., Osterwalder R. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. Biochem Biophys Res Commun. 1992 Jul 31;186(2):867–873. doi: 10.1016/0006-291x(92)90826-7. [DOI] [PubMed] [Google Scholar]
  6. Costello K. B., Stewart D. J., Baffour R. Endothelin is a potent constrictor of human vessels used in coronary revascularization surgery. Eur J Pharmacol. 1990 Sep 21;186(2-3):311–314. doi: 10.1016/0014-2999(90)90450-k. [DOI] [PubMed] [Google Scholar]
  7. Cristol J. P., Warner T. D., Thiemermann C., Vane J. R. Mediation via different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in the systemic circulation and renal vasculature of the anaesthetized rat. Br J Pharmacol. 1993 Mar;108(3):776–779. doi: 10.1111/j.1476-5381.1993.tb12877.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davenport A. P., Kuc R. E., Hoskins S. L., Karet F. E., Fitzgerald F. [125I]-PD151242: a selective ligand for endothelin ETA receptors in human kidney which localizes to renal vasculature. Br J Pharmacol. 1994 Dec;113(4):1303–1310. doi: 10.1111/j.1476-5381.1994.tb17140.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Davenport A. P., Maguire J. J. Is endothelin-induced vasoconstriction mediated only by ETA receptors in humans? Trends Pharmacol Sci. 1994 Jan;15(1):9–11. doi: 10.1016/0165-6147(94)90120-1. [DOI] [PubMed] [Google Scholar]
  10. Davenport A. P., Morton A. J., Brown M. J. Localization of endothelin-1 (ET-1), ET-2, and ET-3, mouse VIC, and sarafotoxin S6b binding sites in mammalian heart and kidney. J Cardiovasc Pharmacol. 1991;17 (Suppl 7):S152–S155. doi: 10.1097/00005344-199100177-00042. [DOI] [PubMed] [Google Scholar]
  11. Davenport A. P., Nunez D. J., Brown M. J. Binding sites for 125I-labelled endothelin-1 in the kidneys: differential distribution in rat, pig and man demonstrated by using quantitative autoradiography. Clin Sci (Lond) 1989 Aug;77(2):129–131. doi: 10.1042/cs0770129. [DOI] [PubMed] [Google Scholar]
  12. Davenport A. P., Nunez D. J., Hall J. A., Kaumann A. J., Brown M. J. Autoradiographical localization of binding sites for porcine [125I]endothelin-1 in humans, pigs, and rats: functional relevance in humans. J Cardiovasc Pharmacol. 1989;13 (Suppl 5):S166–S170. doi: 10.1097/00005344-198900135-00045. [DOI] [PubMed] [Google Scholar]
  13. Franco-Cereceda A. Endothelin- and neuropeptide Y-induced vasoconstriction of human epicardial coronary arteries in vitro. Br J Pharmacol. 1989 Jul;97(3):968–972. doi: 10.1111/j.1476-5381.1989.tb12038.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fukuroda T., Kobayashi M., Ozaki S., Yano M., Miyauchi T., Onizuka M., Sugishita Y., Goto K., Nishikibe M. Endothelin receptor subtypes in human versus rabbit pulmonary arteries. J Appl Physiol (1985) 1994 May;76(5):1976–1982. doi: 10.1152/jappl.1994.76.5.1976. [DOI] [PubMed] [Google Scholar]
  15. Gardiner S. M., Kemp P. A., March J. E., Bennett T., Davenport A. P., Edvinsson L. Effects of an ET1-receptor antagonist, FR139317, on regional haemodynamic responses to endothelin-1 and [Ala11,15]Ac-endothelin-1 (6-21) in conscious rats. Br J Pharmacol. 1994 Jun;112(2):477–486. doi: 10.1111/j.1476-5381.1994.tb13098.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Godfraind T. Evidence for heterogeneity of endothelin receptor distribution in human coronary artery. Br J Pharmacol. 1993 Nov;110(3):1201–1205. doi: 10.1111/j.1476-5381.1993.tb13942.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Grossman E., Rosenthal T., Peleg E., Holmes C., Goldstein D. S. Oral yohimbine increases blood pressure and sympathetic nervous outflow in hypertensive patients. J Cardiovasc Pharmacol. 1993 Jul;22(1):22–26. doi: 10.1097/00005344-199307000-00004. [DOI] [PubMed] [Google Scholar]
  18. Hay D. W., Luttmann M. A., Hubbard W. C., Undem B. J. Endothelin receptor subtypes in human and guinea-pig pulmonary tissues. Br J Pharmacol. 1993 Nov;110(3):1175–1183. doi: 10.1111/j.1476-5381.1993.tb13938.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Howard P. G., Plumpton C., Davenport A. P. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens. 1992 Nov;10(11):1379–1386. doi: 10.1097/00004872-199211000-00010. [DOI] [PubMed] [Google Scholar]
  20. Ihara M., Noguchi K., Saeki T., Fukuroda T., Tsuchida S., Kimura S., Fukami T., Ishikawa K., Nishikibe M., Yano M. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci. 1992;50(4):247–255. doi: 10.1016/0024-3205(92)90331-i. [DOI] [PubMed] [Google Scholar]
  21. Karet F. E., Charnock-Jones D. S., Harrison-Woolrych M. L., O'Reilly G., Davenport A. P., Smith S. K. Quantification of mRNA in human tissue using fluorescent nested reverse-transcriptase polymerase chain reaction. Anal Biochem. 1994 Aug 1;220(2):384–390. doi: 10.1006/abio.1994.1354. [DOI] [PubMed] [Google Scholar]
  22. Karet F. E., Kuc R. E., Davenport A. P. Novel ligands BQ123 and BQ3020 characterize endothelin receptor subtypes ETA and ETB in human kidney. Kidney Int. 1993 Jul;44(1):36–42. doi: 10.1038/ki.1993.210. [DOI] [PubMed] [Google Scholar]
  23. Lüscher T. F., Yang Z., Tschudi M., von Segesser L., Stulz P., Boulanger C., Siebenmann R., Turina M., Bühler F. R. Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res. 1990 Apr;66(4):1088–1094. doi: 10.1161/01.res.66.4.1088. [DOI] [PubMed] [Google Scholar]
  24. Maguire J. J., Bacon C. R., Fujimoto M., Davenport A. P. Myricerone caffeoyl ester (50-235) is a non-peptide antagonist selective for human ETA receptors. J Hypertens. 1994 Jun;12(6):675–680. [PubMed] [Google Scholar]
  25. Maguire J. J., Kuc R. E., O'Reilly G., Davenport A. P. Vasoconstrictor endothelin receptors characterized in human renal artery and vein in vitro. Br J Pharmacol. 1994 Sep;113(1):49–54. doi: 10.1111/j.1476-5381.1994.tb16172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Molenaar P., Kuc R. E., Davenport A. P. Characterization of two new ETB selective radioligands, [125I]-BQ3020 and [125I]-[Ala1,3,11,15]ET-1 in human heart. Br J Pharmacol. 1992 Nov;107(3):637–639. doi: 10.1111/j.1476-5381.1992.tb14498.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Molenaar P., O'Reilly G., Sharkey A., Kuc R. E., Harding D. P., Plumpton C., Gresham G. A., Davenport A. P. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium. Circ Res. 1993 Mar;72(3):526–538. doi: 10.1161/01.res.72.3.526. [DOI] [PubMed] [Google Scholar]
  28. O'Reilly G., Charnock-Jones D. S., Davenport A. P., Cameron I. T., Smith S. K. Presence of messenger ribonucleic acid for endothelin-1, endothelin-2, and endothelin-3 in human endometrium and a change in the ratio of ETA and ETB receptor subtype across the menstrual cycle. J Clin Endocrinol Metab. 1992 Dec;75(6):1545–1549. doi: 10.1210/jcem.75.6.1464662. [DOI] [PubMed] [Google Scholar]
  29. O'Reilly G., Charnock-Jones D. S., Morrison J. J., Cameron I. T., Davenport A. P., Smith S. K. Alternatively spliced mRNAs for human endothelin-2 and their tissue distribution. Biochem Biophys Res Commun. 1993 Jun 30;193(3):834–840. doi: 10.1006/bbrc.1993.1701. [DOI] [PubMed] [Google Scholar]
  30. Peter M. G., Davenport A. P. Selectivity of [125I]-PD151242 for human, rat and porcine endothelin ETA receptors in the heart. Br J Pharmacol. 1995 Jan;114(2):297–302. doi: 10.1111/j.1476-5381.1995.tb13226.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Pollock D. M., Opgenorth T. J. ETA receptor-mediated responses to endothelin-1 and big endothelin-1 in the rat kidney. Br J Pharmacol. 1994 Mar;111(3):729–732. doi: 10.1111/j.1476-5381.1994.tb14798.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pollock D. M., Opgenorth T. J. Evidence for endothelin-induced renal vasoconstriction independent of ETA receptor activation. Am J Physiol. 1993 Jan;264(1 Pt 2):R222–R226. doi: 10.1152/ajpregu.1993.264.1.R222. [DOI] [PubMed] [Google Scholar]
  33. Riezebos J., Watts I. S., Vallance P. J. Endothelin receptors mediating functional responses in human small arteries and veins. Br J Pharmacol. 1994 Feb;111(2):609–615. doi: 10.1111/j.1476-5381.1994.tb14780.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Robaut C., Mondon F., Bandet J., Ferre F., Cavero I. Regional distribution and pharmacological characterization of [125I]endothelin-1 binding sites in human fetal placental vessels. Placenta. 1991 Jan-Feb;12(1):55–67. doi: 10.1016/0143-4004(91)90510-m. [DOI] [PubMed] [Google Scholar]
  35. Saetrum Opgaard O., Adner M., Gulbenkian S., Edvinsson L. Localization of endothelin immunoreactivity and demonstration of constrictory endothelin-A receptors in human coronary arteries and veins. J Cardiovasc Pharmacol. 1994 Apr;23(4):576–583. doi: 10.1097/00005344-199404000-00009. [DOI] [PubMed] [Google Scholar]
  36. Seo B., Oemar B. S., Siebenmann R., von Segesser L., Lüscher T. F. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels. Circulation. 1994 Mar;89(3):1203–1208. doi: 10.1161/01.cir.89.3.1203. [DOI] [PubMed] [Google Scholar]
  37. Sumner M. J., Cannon T. R., Mundin J. W., White D. G., Watts I. S. Endothelin ETA and ETB receptors mediate vascular smooth muscle contraction. Br J Pharmacol. 1992 Nov;107(3):858–860. doi: 10.1111/j.1476-5381.1992.tb14537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Télémaque S., Gratton J. P., Claing A., D'Orléans-Juste P. Endothelin-1 induces vasoconstriction and prostacyclin release via the activation of endothelin ETA receptors in the perfused rabbit kidney. Eur J Pharmacol. 1993 Jun 24;237(2-3):275–281. doi: 10.1016/0014-2999(93)90279-q. [DOI] [PubMed] [Google Scholar]
  39. Wellings R. P., Corder R., Warner T. D., Cristol J. P., Thiemermann C., Vane J. R. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney. Br J Pharmacol. 1994 Feb;111(2):515–520. doi: 10.1111/j.1476-5381.1994.tb14767.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. White D. G., Cannon T. R., Garratt H., Mundin J. W., Sumner M. J., Watts I. S. Endothelin ETA and ETB receptors mediate vascular smooth-muscle contraction. J Cardiovasc Pharmacol. 1993;22 (Suppl 8):S144–S148. doi: 10.1097/00005344-199322008-00039. [DOI] [PubMed] [Google Scholar]
  41. White D. G., Garratt H., Mundin J. W., Sumner M. J., Vallance P. J., Watts I. S. Human saphenous vein contains both endothelin ETA and ETB contractile receptors. Eur J Pharmacol. 1994 May 23;257(3):307–310. doi: 10.1016/0014-2999(94)90144-9. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES